Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
artemether + lumefantrine + albendazole
- Development stage
- Unknown
- Lead developer
- Navrongo Health Research Centre
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Artemether + lumefantrine + albendazole is a combination therapy consisting of the artemisinin-based combination therapy (ACT) artemether-lumefantrine and the anthelmintic agent albendazole. This regimen is used primarily in public health interventions, such as intermittent preventive treatment (IPT) in schoolchildren, to simultaneously address malaria (Plasmodium falciparum) and soil-transmitted helminth infections. Artemether provides rapid clearance of malaria parasites by generating reactive free radicals upon interaction with heme, while lumefantrine offers sustained schizonticidal activity by inhibiting the formation of hemozoin. Albendazole targets intestinal parasites by binding to beta-tubulin and inhibiting microtubule assembly. The combination has been evaluated by the Navrongo Health Research Centre in Ghana to improve health outcomes like anemia and cognitive performance in endemic regions.
- Other names
- artemether-lumefantrine + albendazoleACT + albendazole
02
Targets
β-HematinHemeTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on artemether + lumefantrine + albendazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on artemether + lumefantrine + albendazole.